Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Avidity Biosciences (RNA) Receivables - Net (2022 - 2024)

Avidity Biosciences (RNA) has disclosed Receivables - Net for 3 consecutive years, with $1.6 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Receivables - Net changed N/A year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Mar 2024, changed N/A, and an annual FY2023 reading of $1.1 million, down 53.26% over the prior year.
  • Receivables - Net was $1.6 million for Q1 2024 at Avidity Biosciences, up from $1.1 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $2.4 million in Q4 2022 and bottomed at $1.1 million in Q4 2023.
  • Average Receivables - Net over 3 years is $1.6 million, with a median of $1.4 million recorded in 2023.
  • Peak annual rise in Receivables - Net hit 53.26% in 2023, while the deepest fall reached 53.26% in 2023.
  • Year by year, Receivables - Net stood at $2.4 million in 2022, then crashed by 53.26% to $1.1 million in 2023, then soared by 42.53% to $1.6 million in 2024.
  • Business Quant data shows Receivables - Net for RNA at $1.6 million in Q1 2024, $1.1 million in Q4 2023, and $1.2 million in Q2 2023.